At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 396 enrolled
Drug / intervention
Pimavanserin +1 moredrug
Likely dose
Pimavanserin 34 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Pimavanserin and Placebo for Schizophrenia. Completed, enrolled 396 participants across 105 sites in 10 countries.
Detailed Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesBulgaria, Canada, Czechia, Hungary, Lithuania, Poland, Russia, Serbia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedNov 2016
Primary CompletionMay 2019
Study CompletionJun 2019
TodayJul 2026
First PostedNov 22, 2016
Enrollment StartOct 26, 2016
Primary CompletionMay 28, 2019
Study CompletionJun 25, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.6 years ago
Interventions
Pimavanserindrug
Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
Placebodrug
Placebo, taken as two tablets, once daily by mouth